Planting the seeds of human health. PLANTING THE SEEDS OF HUMAN HEALTH. First in the world to offer the clinically-tested lifespan and healthspan enhancing Osmotin plant protein product line. Available now in the US and worldwide. Visit 9dbio.com for more info. biotech, cell life and death cycle, plant biotechnology, human health, age-reversing, and agriculture

182 similar entities Type: Startup Activities: biotech deeptech agritech Technologies: Synthetic Biology

Leman Biotech, a spin-off company of EPFL, aims at developing and commercializing new metabolic cancer immunotherapies Leman Biotech is a clinical-stage cancer immunotherapy company co-founded by Professor Li Tang of the Swiss Federal Institute of Technology in Lausanne (EPFL) and XtalPi, a leader in AI-driven drug research and development. The company integrates innovative metabolic reprogramming technology with a cutting-edge AI drug discovery platform to develop next-generation cancer immunotherapies. Leman Biotech's Metabolic Reprogramming Technology (Meta 10) represents an innovative approach to combating T-cell exhaustion. Preclinical studies have demonstrated its ability to activate oxidative phosphorylation metabolism in terminally exhausted T cells, restoring …

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

A clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies. At Inventiva, we are united in developing differentiated treatments for MASH and making a meaningful difference in the lives of those affected. Recognizing that MASH is not just a liver disease but also a cardiometabolic condition, we have purposefully designed a potential oral therapy — currently in clinical development — intended to restore metabolic balance at the source and directly target inflammation and fibrosis. Our goal is to bring relief to patients across the MASH patient population, addressing a critical unmet need in a progressive and life-threatening …

95 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing Glycan Mediated Therapy GlycoEra is developing biologics to selectively target the root cause of many autoimmune diseases: a specific circulating protein (autoantibody). Our approach enables us to degrade targets rapidly, selectively, and deeply while avoiding broader dampening of the immune system. This offers many potential benefits over existing broad-spectrum immune-suppressing therapies, including an improved safety profile and the potential for earlier disease intervention – which could improve patient quality of life, limit long-term complications and lower overall healthcare costs. Our best-in-class, extracellular degrader BiNDTM platform (Biologic Natural Degrader), allows us to target and rapidly, deeply degrade any circulating protein …

208 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Using mesenchymal stem cells to produce therapeutically meaningful extracellular vesicles. We are a recently incorporated limited company, spun out from the University of York from the Genever lab (www.geneverlab.info), which has over 20 years of experience in cell biology and regenerative medicine. We focus on musculoskeletal regeneration using mesenchymal stem cells (MSCs), with a view to translate our body of work into cutting edge therapeutics. Our current focal point is the field of extracellular vesicles (EVs), which have recently gained substantial traction as a next-generation therapeutic modality. We believe that current approaches have room for improvement in terms of consistency …

93 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

We are developing first-in-class small molecules to improve mitochondrial function and reduce chronic inflammation. We are developing first-in-class small molecules against a novel target to improve mitochondrial function and reduce chronic inflammation to treat age-related diseases.

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science-driven efficacy Founded in 2010, Biomeostasis is a leading Preclinical CRO that offers in vivo research services in the fields of Metabolic, GastroIntestinal & Muscle-Wasting Diseases. For over 15 years, we have been assessing the Efficacy & Mechanisms of action of Health Products that address conditions such as Obesity, Diabetes, MASLD/MASH, Atherosclerosis, Binge-eating, IBD, Sarcopenia, Cachexia, Duchenne Muscular Dystrophy (DMD)... Complementary to our in vivo pharmacology services, we offer Histology and Omics enabling deciphering the efficacy and MoA of Health Products in the metabolic, GI and muscle-wasting spaces. Localisation : Marseille - France preclinical, obesity, diabetes, gastrointestinal disorders, tailor-made rodent …

55 similar entities Type: Startup Activities: deeptech

Reverse metabolic disease, don't manage it. Virta Health is on a mission to reverse metabolic disease in one billion people — and we’re already proving it’s possible. Through AI-powered, personalized nutrition therapy and human care, we help members address the root cause of metabolic disease, reducing or eliminating medications and building lasting health — without surgery or deprivation. Virta partners with the nation’s largest employers, payers, and pharmacy benefit managers to improve the health of their members while reducing costs. Headquartered in Denver, Colorado, Virta is transforming how metabolic health care is delivered at scale. healthcare, diabetes, corporate wellness, health …

63 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: SaaS

Genetic medicines for age-related diseases Oisín Biotechnologies is developing a new class of genetic medicines that target the biology of aging. We don't make pills or supplements; we build powerful, redosable genetic therapies and start with indications regulators already understand, so we can attack the mechanisms of age-related decline on a path that leads to approval. Our therapies are built on the Fusogenix Proteo-Lipid Vehicle (PLV), a non-viral delivery technology that fuses directly with target-cell membranes to deliver both DNA and RNA payloads. Delivery has been the Achilles' heel of genetic medicine. Viral approaches can't be safely redosed, carry limited …

89 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Levearging the therapeutic potential of mitochondria cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT). The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell. Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation. Therapeutic Mitochondria Transfer, Mitochondria, Ischemia-Reperfusion Injury, and Solid Organ Transplantation

60 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

FREEZING THE HUNGER FEELING - A new weight-loss therapy for the treatment of obesity - one-off and long-term effect. Sedivention - Fight obesity where it starts! 20 minutes will change your life. A new weight-loss therapy to reduce the hunger feeling – fast, effective, and longterm. No implant, no surgery, no lifelong drug intake. Obesity, MedTech, Life-Science, Healthcare, Diabetis, Weight loss therapy, Obesity startup, Weight-loss therapy, cryo-ablation, Treatment of obesity, Kryoablation, Fight obesity, and Therapy weight loss

64 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Targeting Beta Cell recovery in Diabetes DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world. Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits. DiogenX is headquartered in Marseille, with labs in Nice (France). Biotechnology and Diabetes

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

BariaTek is a clinical stage company dedicated to treating obesity via a reversible non-invasive endoscopic approach. BariaTek Medical is a clinical stage company dedicated to addressing obesity via minimally invasive endoscopic approaches. Obesity is one of the most debilitating pandemics affecting humanity: More than 2 billion people are overweight of which 1 billion suffer from obesity. People suffering from obesity tend to lead shorter, less healthy, lives. Treating overweight-related conditions (diabetes, hypertension, sleep apnea and others) is projected to cost G-20 nations on average 8.7% of their health budgets over the next three decades which is estimated by the United …

60 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

ON DEMAND CYTOKINE Company Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response. ON DEMAND CYTOKINE, CYTOKINE DRUG, IMMUNO-ONCOLOGY, and TARGETED ONCOLOGY

166 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Science of certainty Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile …

118 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Removing the Guesswork from Medicine Olaris is a precision medicine company leveraging metabolomics and machine learning for the discovery and development of its myOLARISTM diagnostics products, which aim to optimize treatments and outcomes for individual patients. Metabolite diagnostics empower therapeutic selection, treatment effectiveness monitoring, disease diagnosis, and target identification across indications and therapeutics areas, including oncology, solid-organ transplant, and neurodegeneration. Our mission is to remove the guesswork from medicine. Diagnostics, Machine Learning, Metabolomics, NMR, Mass Spectrometry, Statistics, Transplant, and Oncology

111 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning

Better Science, Better Health 🧬 The OptiBiotix difference; improving health and wellbeing. OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. OptiBiotix has established a pipeline of …

61 similar entities Type: Startup Activities: healthtech deeptech Technologies: SaaS

Giving Life to Science PureTech Health is a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value. We do this through a proven, capital-efficient R&D model focused on opportunities with validated pharmacology and untapped potential to address significant patient needs. This strategy has produced dozens of therapeutic candidates, including three that have received U.S. FDA approval. By identifying, shaping, and de-risking these high-conviction assets, and scaling them through dedicated structures backed by external capital, we accelerate their path to patients while creating sustainable value for shareholders. For more information, visit www.puretechhealth.com or connect with us …

182 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and …

402 similar entities Type: Startup Activities: deeptech Technologies: A.I. Synthetic Biology

Bringing energy to life We are a Phase 3 ready clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field …

62 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Generate human-specific efficacy and safety data with PhysioMimix® microphysiological systems. CN Bio is a leading Organ-on-a-chip (OOC) company that enables scientists to improve the accuracy and efficiency of preclinical drug discovery. Our PhysioMimix® Core microphysiological system, 3D-validated cells, consumable plates, and Contract Research Services facilitate the prediction of human responses to drug exposure, in the presence or absence of disease, so that new medicines can be brought to market more rapidly, cost-effectively and using fewer animals. Utilizing primary cells, our perfused single (Lung, Liver), and multi-organ (Gut/Liver, Lung/Liver) models recapitulate the microarchitecture, microenvironment, and function of their human counterparts in …

202 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

FROM DISCOVERY TO THERAPEUTICS MT-act is a CNRS spin-off. #techtransfer We develop class compounds to treat human pathologies that share a common molecular defect; dysfunction of the skeleton of the cells called microtubules - abbreviated MT. Stiffening of the skeleton of our cells is a central disease driver. That is why we act on them. We developed a technology platform to charter an entirely neglected pharmaceutical space. MT-act prioritizes indications based on scientific evidence, proven unmet medical needs and where the roadmap to patients is feasible and desired. Drug development, Microtubules, Tubulin code, Preclinical, Drug screening, first-in-class, and drug discovery

153 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Leading biotech in the development of innovative microbiome-based biotherapies YSOPIA Bioscience is a clinical-stage biotech company developing cutting-edge biotherapies based on the gut microbiome. Our goal is to bring safe & efficient solutions to patients with high unmet medical needs. Microbiome, Obesity, Gut modulator, Cardiometabolism, Cardiometabolic diseases, Microbiota, and Gut microbiota

298 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Repairing the human powerplant: mitochondrial recycling therapy ANKIAL Pharma is a biotech-Pharma start-up company that is developing a drug to treat hypertrophic cardiomyopathy (HCM), a heart disease that affects 20 million patients worldwide. The drug ANK0121 (patented by INSERM/Bordeaux Hospital and University) acts on mitochondria, the powerplant of the heart. This technology promotes mitochondrial recycling to improve heart bioenergetics and prevent hypertrophic cardiomyopathy in various in vivo models of HCM. ANKIAL operates from the preclinical phase to the marketing authorization. The team includes 5 founders. The CEO Bruno LEGRAND has 25 years of expertise in the pharmaceutical industry sector (cardio-metabolic …

86 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Ketogenic Medical Food DADFMS R&D Facilitate Therapeutic Ketogenic Diets. KetoM+ : Ketogenic Medical Food DADFMS KetoM+ develops a new generation of ketogenic products adapted to therapeutic diets. Ketogenic diets can be challenging to manage for some populations (pediatric and adults) because of the high fat low carb ratio. Many neurological disorders like epilepsy have no real effective treatment. Metabolic diets have powerful therapeutic potential when well done. KetoM+ brings the solution with medically adapted products elaborated with a pharmaceutical approach. KetoM+ high quality ingredients and the respect to the palatability of the products make them unique. Medical Nutrition, Ketogenic diets …

55 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

SITERA is developing new therapies to tackle neurodegenerative diseases and meet the urgent needs of all patients SITERA Pharmaceuticals is a preclinical-stage biotech developing small molecule therapeutics that target Mitochondria-Associated Membranes (MAMs), a critical hub for neuronal signaling and metabolism. Our mission: deliver innovative therapies for patients with rare and prevalent neurodegenerative diseases who have run out of options. Leveraging a proprietary platform combining cutting-edge chemistry and biology, we design potent, selective, and safe CNS therapeutics, addressing some of the most challenging unmet needs in neurology. Biotechnology, Neurodegenerative diseases, and Central Nervous System

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Fighting chronic and fatal diseases Tirecat Health is a company developing a family of novel polymers with amazing potential in the healthcare field. We are propelled with purpose to fight chronic and fatal diseases affecting patients worldwide using our revolutionary technology to improve their quality of life. In order to make this purpose a reality, the company is preparing to move towards the clinical phase to demonstrate the astonishing results seen in preclinical trials.

300 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Leading preclinical CRO specializing in metabolic disorders. Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, ...) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions …

83 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Incipiam means ”I will begin” and that is where we believe we are – at the forefront of a paradigm shift in metabolic disease treatment. Most treatment options currently in development for metabolic disease focus on reduction of energy intake. While this is important, we see a new era of weight loss therapeutics emerging, where reduction in energy intake is insufficient to advance both the understanding of metabolic disease but also to drive development of novel treatments. At Incipiam Pharma, we're pioneering the next wave of weight loss therapeutics, targeting energy expenditure to revolutionize treatment for those living with obesity …

58 similar entities Type: Startup Activities: healthtech deeptech biotech Technologies: Synthetic Biology

Medincell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options. Our mission is to contribute to the improvement and protection of the health of populations across the world. The fair sharing of the value created with all our employees is the foundation of our business model. The sustainability of MedinCell is an essential condition …

577 similar entities Type: SMB Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Transforming lives by accelerating innovation in cardiometabolic health Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Our most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing. We are also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy, improved tolerability, and healthier weight loss. …

120 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Decoding Metabolic Health with Explainable AI At MedInsights, we are dedicated to bringing optimized therapeutic options for patients suffering from metabolic, cardiometabolic, neurometabolic and rare diseases with high unmet needs. Our internal drug repositioning engine, NexusRx, serves as a cornerstone for our discovery research, employing internal sets of proprietary algorithms to detect unknown and unforeseen relationships between disease-targets-drugs. This opens up preclinical validation opportunities which we perform in close partnerships with our academic collaborators. We envision to perform clinical trials and bring therapeutics from lab to bed side. Crunchbase profile: https://www.crunchbase.com/organization/medinsights-0569 Biotech, Data Science, Healthcare, Computer Vision, Generative AI, Network …

525 similar entities Type: Startup Activities: deeptech biotech Technologies: A.I. A.I. - Machine Learning Data Analytics

Pioneering health solutions since 1993. Committed to innovative technology applications in health, we explore Longevity in Japan, delve into Microbiome and Mitochondria research, and contribute to advancements in Anti-Age clinics. Our mission is to empower individuals for a healthy, energetic life.

133 similar entities Type: SMB Activities: deeptech healthtech

Prescription digital therapeutics powered by personalized nutrition. Reimagining medicine At Perfood, we translate state-of-the-art data and medical science into therapy. We create software, that precisely identifies what actions need to be take on a personalized level, to prevent or fight diseases. Using sensors, lab results and holistic analyses, we derive therapeutic angles and deliver them in a slick, easy-to-use way, making them accessible for all patients. We call this approach digital therapeutics. A digital solution that is just as effective as a drug. But without side effects. We believe that our genetic heritage is an elementary compound of our health. …

101 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

The Tendon Health Company We are The Tendon Health Company, a clinical-stage biotech developing novel medicines for tendon disease. Tendinopathy represents a huge unmet need for millions of patients worldwide and is a significant cost to healthcare systems. Causeway has developed a proprietary microRNA mimic, microRNA29a, that acts through multiple pathways to treat chronic tendon disease. Causeway’s initial therapeutic focus is for treatment of lateral epicondylitis (tennis elbow), and the rotator cuff. TenoMIR restores tendon structure, reducing pain and improving function. It promises to transform patient outcomes and enable them to reclaim their active lives. Causeway is leading the race …

83 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Making cell therapies more durable and effective through metabolic reprograming. At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info. Longevity, Mitochondria, Cellular rejuvenation, Immunotherapy, and CAR T cell therapy

80 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Performance nutrition that unlocks your full potential. Performance nutrition that unlocks your full potential. We provide personalized products and 1:1 Registered Dietitian support to empower active people to reach their unique goals by transforming their health.

91 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Reduce media costs and maximize cell viability. 3DBT: Crowding technology for meat-tech and biopharma. 3D Bio-tissues (3DBT) is a biotechnology company redefining the efficiency of cell-based therapies and cellular agriculture. We specialize in the development of macromolecular crowders—simple, powerful media additives designed to mimic the natural physiological environment, accelerating growth and significantly reducing operational costs. At the core of our innovation is a commitment to making complex biology scalable. By optimizing the way cells interact with their environment, we help our partners move from lab-scale success to industrial-scale reality. Our Core Solutions: CityMixTM | Transforming Cultivated Meat: The biggest barrier …

81 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Biopharmaceutical company focused cardiometabolic and inflammatory diseases Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass thereby improving body composition and physical function. Sabizabulin, a microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease.

111 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Tackling metabolic disorders with non-coding RNAs Resalis Therapeutics’ transformative metabolic disease approach targets a master regulator of key pathways underlying obesity and fatty liver disease. The company is applying its unique understanding of the non-coding RNA drug modality and lipid metabolism to develop its lead program, RES-010, into a safe and convenient treatment providing disease-modifying therapeutic impact including durable weight loss and reduction of hepatic steatosis. Building on robust preclinical evidence, Resalis will rapidly bring RES-010 into clinical trials for a range of metabolic disorders.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming lives with groundbreaking treatments Coultreon Biopharma's mission (formerly Onco3R Therapeutics) is to develop life-changing medicines for patients affected by chronic inflammatory diseases of high unmet medical needs. The team is leveraging their knowledge and expertise to bring transformative innovations to patients suffering from auto-immune diseases. In this field, there is an urgent need for more convenient oral drugs that can offer greater efficacy with a better safety profile. Drug Discovery, Drug Development, Immunology, Biotech, and R&D

826 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Une entreprise spécialisée dans le développement de thérapies transformatrices ayant un impact sur la longévité. Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging. Our small molecules are aimed at stimulating biological resilience to stress during aging. Ruvembri - in regulatory and clinical phases - is our leading drug candidate is administered orally: • for the treatment of severe respiratory events related to COVID-19 following positive results in Phase 2/3 clinical study (COVA) • for the treatment of reduced mobility in elderly patients with sarcopenia, …

263 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

"Innovative medicine for everyone, everywhere"​ "Innovative medicine for everyone, everywhere"​ Listed on the Euronext stock market, Adocia is a clinical-stage biotech company specialized in the development of best-in-class medicine relying on innovative formulations of already-approved therapeutic proteins. Adocia is specialized in diabetes and obesity. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and safety of therapeutic proteins and their ease of use for patients. For more information, visit our website: www.adocia.com For careers offers, please click to the following link : https://www.adocia.com/careers/adocia-careers/ Therapeutic proteins, BioChaperone®, Next-generation injectables for diabetes treatment, Ultra-rapid Insulin, Multi-agents injectable combination, Diabetes, Metabolic …

152 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Reducing the metabolic impact of modern meals, one meal at a time. SIGRID Therapeutics is a metabolic health company developing gut-local technologies designed to reduce the metabolic impact of modern meals. Powered by patented SiPore® technology, SIGRID products work locally in the gastrointestinal tract, where precisely engineered pores interact with digestive enzymes involved in carbohydrate and fat digestion. By slowing the breakdown of nutrients during digestion, SiPore® supports steadier post-meal patterns and improved metabolic stability over time. Our work is built on a simple idea: modern food environments deliver rapid metabolic load, creating repeated spikes and swings that place strain …

50 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Treating Neurodegenerative Disease by Restoring Autophagy At Samsara Therapeutics, we’re on a mission to unlock the full potential of autophagy activation in combating age-related neurodegenerative diseases. Our innovative approach aims to delay the progression of several debilitating conditions, offering new possibilities for patients and their families. biotechnology, biopharmaceuticals, rare disease, neurodegeneration, longevity, drug discovery, and drug development

428 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders We are a clinical-stage biotechnology company combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders, with the hope of helping patients overcome their disease and live a better life. We are pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. In modulating the function of profound intracellular regulators, our medicines have the potential for significant clinical impact in the most difficult-to-treat diseases. We believe the wide-ranging impact of our therapeutic platforms can be …

435 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Target-led management of the causes of metabolic disease Diabetes currently effects over 537 million adults worldwide, with obesity-driven Type 2 Diabetes accounting for over 90% of cases. Dia Beta Labs build on over 30 years of high-impact research from our founding research group at Ulster University to realise the potential of next-generation therapeutics for metabolic disease. It is our goal to impart significant and much-needed change in the management of the global diabetes/obesity crisis. Diabetes, Peptide Development, Metabolic Disease, Obesity, and Peptide Therapeutics

73 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cell rejuvenation to rewind age driven diseases Operating at the intersection of machine learning and cell biology, Shift’s target discovery platform leverages large-scale proprietary datasets and virtual cell models to link cellular aging to disease states. The Company is progressing a pipeline of cell rejuvenation targets, identifying an initial siRNA program in liver fibrosis (MASH and non-MASH) with unique expansion potential to the most advanced and age-driven forms of fibrosis. Cambridge (UK) based with a team spanning Longevity, virtual cells, siRNA and liver disease, Shift is open to strategic partnerships that accelerate the first medicines capable of prolonging both healthspan …

70 similar entities Type: Startup Activities: deeptech biotech healthtech Technologies: A.I. Synthetic Biology

Pioneering Regenerative Macrophage Therapy in Inflammatory and Fibrotic Diseases Resolution Therapeutics is a clinical-stage biotechnology company developing regenerative macrophage therapy to treat inflammatory and fibrotic diseases. The company was spun out of the Forbes Lab at University of Edinburgh's Centre for Regenerative Medicine in 2020 and is backed by Syncona. Our initial focus is in end-stage liver disease (advanced cirrhosis). It is the only chronic disease still on the rise in western countries, and affects millions of people worldwide. Unfortunately, only supportive therapies are currently available. For patients with end-stage liver disease the only therapeutic option is liver transplantation, a …

122 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Danish biotech company developing peptide-small molecule drugs for treatment of obesity Ousia Pharma is a biotech spin-out from the University of Copenhagen developing novel peptide-drug conjugates for treatment of obesity and metabolic diseases. The company uses a proprietary targeting approach in which peptides are used to deliver modulators of synaptic plasticity to drive a potent and sustained weight loss without compromising safety. A main objective of Ousia Pharma is to advance the development of the lead weight loss drug candidate (OP-56) within general obesity.

64 similar entities Type: Startup Activities: healthtech Technologies: Synthetic Biology

Developing 1st-in-class therapeutics based on the profound understanding of omega-3 fatty acid metabolism OMEICOS Therapeutics has discovered a series of metabolically robust synthetic analogues of omega-3 fatty acid-derived epoxyeicosanoids that have the potential to treat mitochondrial dysfunction, inflammatory, cardiovascular and other diseases. Epoxyeicosanoids activate cell type-specific endogenous pathways that promote organ and tissue protection. OMEICOS’ small molecules are orally available and show improved biological activity and pharmacokinetic properties compared to their natural counterparts. The currently active PMD-OPTION Phase 2a clinical study is evaluating OMEICOS’ lead development program OMT-28 in patients with Primary Mitochondrial Disease. Drug development, Cardiovascular Research, and Mitochondrial …

67 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Technology-driven biotech with an AI-powered miniprotein RnD platform VRG Tx is technology-driven biotech with a drug discovery platform that integrates AI with wet lab processes to develop next-generation therapeutics. Our vision is to cure diseases through previously undruggable targets and inaccessible mechanisms of action. medicinal biotechnology, research, immunology autoimmune deases , translational health research, use of genetic engineering in medicine, anti cancer drug discovery, oncological drugs, autoimmune diseases, translational research, peptide, cellandgenetherapy, and genetherapy

589 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pioneering cellular rejuvenation using epigenetic restoration to reverse diseases of aging At Life Biosciences, we are on a mission to reverse age-related diseases. Our platform, termed epigenetic restoration, has been shown to rejuvenate cells in preclinical models with profound therapeutic effect. It has the potential to rejuvenate cells and restore function in many age-related diseases. We are the sole company with intellectual property covering the therapeutic use of our epigenetic restoration technology. We are also the only company to have received FDA approval to advance this technology into human clinical studies. While our initial clinical trial is for optic neuropathies, …

93 similar entities Type: Startup Activities: biotech deeptech silvertech Technologies: Synthetic Biology

AI-based Metabolic Platform for Precision Medicine ReviveMed, an MIT spinout, is an AI-driven metabolomics platform for precision medicine. Our patented technology detects 20x more metabolites per patient than traditional methods, enabling the creation of digital metabolic twins. Digital metabolic twins are virtual patient models representing individuals’ metabolic networks within a multi-omic context to simulate health and disease. We have a pipeline of metabolic twins for oncology and cardio-metabolic diseases, such as renal cell carcinoma, MASH, and obesity. Our metabolic twins increase trial success rates by predicting which patients respond to drugs and reducing trial sizes by simulating disease progression in …

68 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. A.I. - Machine Learning Synthetic Biology

Formulating the Future of BiologicsTM Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, HyperconTM, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are …

276 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Unique technology and novel data for personalized and optimal treatment of high cholesterol MONCYTE Health has a unique proprietary technology to quantify individual differences in cellular lipid uptake and storage which contribute to high blood cholesterol and the effectiveness of common lipid-lowering drugs. The readouts are derived from white blood cells, including monocytes, which play key roles in atherosclerotic plaque formation and inflammation, linking directly to cardiovascular risk. Precisely quantifying these individual differences enables personalized treatment strategies in combination with risk assessment which can help patients more effectively achieve optimal blood cholesterol levels faster, and thereby reduce the risk for …

66 similar entities Type: Startup Activities: deeptech biotech Technologies: Data Analytics Synthetic Biology

#AI #biopharma #therapeutics #mitochondrial #proteinhomeostasis #oncology #neurology #raredisease #drugdiscovery BPGbio is a clinical-stage biopharmaceutical company focused on developing mitochondrial-targeted therapies for patients. The company’s approach is grounded in advancing therapeutics that restore cellular energy regulation and address mitochondrial dysfunction, a central driver of disease across multiple high-burden indications. BPGbio’s lead clinical candidate, BPM31510, is a potential first-in-class mitochondrial metabolic modulator currently in clinical development for Primary CoQ10 Deficiency (PCQD) and Glioblastoma. The asset has also completed a phase I trial in Epidermolysis Bullosa (EB). The company is currently exploring the potential of BPM31510 in small cell carcinoma (SCC), pancreatic cancers, …

74 similar entities Type: SMB Activities: biotech deeptech Technologies: A.I. Data Analytics Synthetic Biology

NewAmsterdam Pharma Corporation is a clinical-stage biopharma company creating therapies for cardiometabolic diseases. This page is intended for US audiences. Founded in 2019, NewAmsterdam Pharma Corporation is a late-stage clinical biopharmaceutical company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. The Company is investigating a selective cholesteryl ester transfer protein (CETP) inhibitor as an LDL-C lowering therapy for patients who cannot be treated optimally with currently available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia …

185 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology